Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes

Table 2 Therapeutic use of hyperthermic intraperitoneal chemotherapy, controlled trials: Study and population characteristics

Year	Ref./trial	Controlled trial phase	Patient cohort	Positive peritoneal cytology	PCI	Median PCI	Ascites	N stage	Syncronous metastasis only
2020	Blum Murphy et al[31]	1	27	Yes	< 8 (52%), 8-14 (15%), 15-21 (11%), > 21 (22%)	6	Admitted (41%)	ND	Yes
2020	Yu et al[30]	2	38	Yes	≤ 20 (100%)	8.8	Admitted	72.2% ypN+ (convertion to surgery group)	Yes
2020	PERISCOPE 1	1 and 2	25	Yes	< 7 (100%)	2	ND	68% ypN+	Yes1
2021	Badgwell et al[35]	2	20	Yes	0 (40%), 1-2 (35%), > 3 (25%)	ND	ND	70% ypN+	Yes
2023	Green et al[34]	2	41	Yes	≤ 10 (100%)	2	Excluded if > 500 cc	68% ypN+	Yes

¹Small bowel or mesenteric localizations were excluded.

All patients have peritoneal metastases or positive peritoneal cytology and no liver or lung metastasis. ND: Not declared; PCI: Peritoneal cancer index.